DJIA 16,731.08 -73.63 -0.44%
NASDAQ 4,390.13 -31.96 -0.72%
S&P 500 1,933.58 -12.58 -0.65%
market minute promo

Gilead Sciences (NASDAQ: GILD)

104.55 -1.04 (-0.98%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

GILD $104.53 -1.00%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $105.00
Previous Close $105.59
Daily Range $103.61 - $105.91
52-Week Range $58.81 - $110.64
Market Cap $158.0B
P/E Ratio 23.78
Dividend (Yield) $0.00 (0.0%)
Volume 5,093,181
Average Daily Volume 14,693,490
Current FY EPS $7.26





Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website:

News & Commentary

Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?

Speculation that Achillion could be a takeover target was dampened following Johnson & Johnson's acquisition of Alios this week.

Stock Market News for October 02, 2014 - Market News

Merrill Lynch’s Top Catalyst Ideas for the Fourth Quarter

Seattle Genetics-Takeda Reveal Impressive Adcetris Data - Analyst Blog

Machines Rule, Bears Drool - Video Blog

Why Gilead Sciences (GILD) Stock Is Declining Today

Round 2 of Gilead Sciences, Inc.'s Offensive Begins

A key European advisory panel recommends Gilead's Harvoni for EU approval.

#PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed

#PreMarket Primer: Wednesday, October 1: First Case Of Ebola In The US Confirmed

AMAG Up on Roughly $1B deal with Lumara to Widen Portfolio - Analyst Blog

See More GILD News...

GILD's Top Competitors

GILD $104.55 (-0.98%)
Current stock: GILD
AMGN $137.10 (-1.24%)
Current stock: AMGN
CELG $91.81 (-1.73%)
Current stock: CELG
$0.00 (0.00%)
Current stock: